2019
DOI: 10.1111/nan.12556
|View full text |Cite
|
Sign up to set email alerts
|

Knockout of apolipoprotein A‐I decreases parenchymal and vascular β‐amyloid pathology in the Tg2576 mouse model of Alzheimer's disease

Abstract: Aims Apolipoprotein A‐I (apoA‐I), the principal apolipoprotein associated with high‐density lipoproteins in the periphery, is also found at high concentrations in the cerebrospinal fluid. Previous studies have reported either no impact or vascular‐specific effects of apoA‐I knockout (KO) on β‐amyloid (Aβ) pathology. However, the putative mechanism(s) by which apoA‐I may influence Aβ deposition is unknown. Methods We evaluated the effect of apoA‐I deletion on Aβ pathology, Aβ production and clearance from the b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
11
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(12 citation statements)
references
References 77 publications
(103 reference statements)
1
11
0
Order By: Relevance
“…Animal studies have illustrated that a lack of APOA-I exacerbates-while overexpression of human APOA-I alleviates-CAA in the APP/PS1 mouse model of AD, without affecting parenchymal Aβ deposition [83,84], consistent with a prior study in a different line of APOA-I-deficient AD mice (PD-APP) [85]. On the contrary, a recent study using another transgenic mouse model of AD (Tg2576) showed that lack of APOA-I decreased both parenchymal and vascular Aβ pathology [86]. However, another recent study with APP/PS1 mice extended prior findings, in which APOA-I deficiency increased CAA and neuroinflammation as well as cortical Aβ deposition [87].…”
Section: Amyloid Pathologysupporting
confidence: 87%
“…Animal studies have illustrated that a lack of APOA-I exacerbates-while overexpression of human APOA-I alleviates-CAA in the APP/PS1 mouse model of AD, without affecting parenchymal Aβ deposition [83,84], consistent with a prior study in a different line of APOA-I-deficient AD mice (PD-APP) [85]. On the contrary, a recent study using another transgenic mouse model of AD (Tg2576) showed that lack of APOA-I decreased both parenchymal and vascular Aβ pathology [86]. However, another recent study with APP/PS1 mice extended prior findings, in which APOA-I deficiency increased CAA and neuroinflammation as well as cortical Aβ deposition [87].…”
Section: Amyloid Pathologysupporting
confidence: 87%
“…Furthermore, apoa1 knockout mice show increased beta-amyloid (Aβ) deposition within the cerebrovascular wall and increased vascular inflammation. However, other studies reported either no difference [ 174 ] or reduced Aβ deposition within the vascular wall [ 175 ]. Mice overexpressing human APOA1 have reduced vascular inflammation and Aβ deposition [ 176 ].…”
Section: Hdl and Blood–brain Barrier Function In Stroke And Neurodegenerative Diseasesmentioning
confidence: 99%
“…Spinster homolog 2 (SPNS2) regulates the levels of Sphingosine-1-phosphate (S1P) gradient that controls lymphocyte trafficking 23 . In addition, dnaJ homolog subfamily C member 25 (DNAJC25) can significantly increase cell apoptosis, and its overexpression inhibits cell growth 24 . Deletion of inositol polyphosphate multikinase (IPMK) in cell lines and mice virtually abolished lipophagy, caused liver damage and inflammation, and impaired hepatocyte regeneration 25 .…”
Section: Resultsmentioning
confidence: 99%